Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Nov 1.

Published in final edited form as: Stem Cell Res. 2010 Aug 6;5(3):212–225. doi: 10.1016/j.scr.2010.07.003

(A); Xenograft tumors generated from both unfractionated and sorted CD45+CD19− tumor cells (Pt1) displayed pathological features resembling the original patient tumors. The xenograft tumors and the patient’s original tumor cells expressed comparable levels of CD19, CD20, cyclin D1 and Ki-67 proliferation antigens. Cells from patient PBMC were examined for Ki-67 and cyclin D1 expression (arrows). At least five sections from each xenograft tumor were analyzed. Only Pt1 derived tumors are shown even though all xenograft tumors derived from eight different patients were analyzed. Other xenograft tumors also generated similar results.

(B); Immunohistochemical analysis of CD45+CD19− and CD45+CD19+ xenograft tumors. CD45+CD19− and CD45+CD19+ xenograft tumors (Pt4) are immunostained for human CD19 and cyclin D1. Arrows in each panel indicate representative signals.

(A); Xenograft tumors generated from both unfractionated and sorted CD45+CD19− tumor cells (Pt1) displayed pathological features resembling the original patient tumors. The xenograft tumors and the patient’s original tumor cells expressed comparable levels of CD19, CD20, cyclin D1 and Ki-67 proliferation antigens. Cells from patient PBMC were examined for Ki-67 and cyclin D1 expression (arrows). At least five sections from each xenograft tumor were analyzed. Only Pt1 derived tumors are shown even though all xenograft tumors derived from eight different patients were analyzed. Other xenograft tumors also generated similar results.

(B); Immunohistochemical analysis of CD45+CD19− and CD45+CD19+ xenograft tumors. CD45+CD19− and CD45+CD19+ xenograft tumors (Pt4) are immunostained for human CD19 and cyclin D1. Arrows in each panel indicate representative signals.